anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The utility model discloses a facial mask cloth with an acupoint hint function. The facial mask cloth with the acupoint hint function comprises a mast body. The mask body is provided with eye holes, a mouth hole and a nose hole. The facial mask cloth with the acupoint hint function is characterized in that the mask body is further provided with a plurality of acupoint hint convex portions corresponding to face acupoints of a person. When a user uses the facial mask cloth with the acupoint hint function to apply face, the user can easily find acupoints on the face by using fingers through the acupoint hint convex portions disposed on the mask body with no need of comparison of a mirror and an acupoint map or with the help of a professional. The user can conveniently, promptly and accurately message the acupoints on the face. The facial mask cloth with the acupoint hint function adds the acupoint hint function to an existing mask cloth and has a practical value and an application prospect.
Participants will receive Treatment B in Treatment Period 1, followed by Treatment C in Treatment Period 2 and then Treatment A in Treatment Period 3 on Day 1 of each Treatment Period under fasted conditions. Each treatment period will be separated by a washout period of at least 5 days and maximum 21 days between subsequent intakes of study intervention.
OBJECTIVE: To evaluate the predictive value of pre-hepatectomy dynamic circulating tumor DNA (ctDNA) on pathologic response to preoperative chemotherapy and recurrence after liver resection for colorectal liver metastases (CRLM).
BACKGROUND: Pathologic response is a predictor of clinical outcomes for patients undergoing hepatectomy for CRLM. Postoperative ctDNA has been proven to be sensitive for recurrence detection. However, few studies investigate the impact of pre-hepatectomy ctDNA on pathologic response and recurrence.
METHODS: Patients with potential resectable CRLM underwent preoperative chemotherapy and hepatectomy between 2018 and 2021 was considered for inclusion. Plasma ctDNA was collected before and after preoperative chemotherapy. Pathologic response was analyzed for all patients after liver resection. Recurrence free survival was compared between patients with different ctDNA status and different pathologic response. The relation between ctDNA and pathologic response was also analyzed.
RESULTS: A total of 114 patients were included. ctDNA was detectable in 108 of 114 patients (94.7%) before chemotherapy, in 56 of 114 patients (49.1%) after chemotherapy. Patients with ctDNA positive at baseline and negative after chemotherapy had significantly longer RFS (median RFS 17 vs 7 months, p = 0.001) and HRFS (median HRFS unreached vs 8 months, p < 0.001) than those with ctDNA persistently positive after chemotherapy. Two patients (1.6%) had a pathologic complete response and 56 patients (45.2%) had a pathologic major response. Post-chemotherapy ctDNA- was associated with improved major pathologic response (53.4% vs 32.1%, p = 0.011). In the multivariable analysis, ctDNA- after chemotherapy (HR 0.51, 95% CI 0.28-0.93), major pathologic response (HR 0.34, 95% CI 0.19-0.62) and surgery combined with radiofrequency ablation (HR 2.62, 95% CI 1.38-5.00) were independently associated with RFS (all p < 0.05).
CONCLUSIONS: Pre-hepatectomy dynamic monitoring of ctDNA could predict pathologic response to preoperative chemotherapy and post-hepatectomy recurrence in CRLM patients. Negative ctDNA after preoperative chemotherapy was associated with better tumor regression grade and recurrence-free survival, which might be used to guide pre-hepatectomy chemotherapy and predict prognosis.
This study assessed anxiety status and coronary flow reserve in hypertensive patients to investigate the effects of anxiety on coronary microcirculatory function.The hypertensive patients with chest pain for suspicious coronary heart disease were seriesly enrolled. All the patients underwent coronary angiography or coronary CT angiography to exclude the diagnosis of obstructive coronary artery disease . Coronary flow reserve (CFR) is an integrated measure of flow through both the large epicardial arteries and the coronary microcirculation. In the absence of obstructive stenosis of the epicardial arteries, CFR is an indicator of coronary microcirculatory function，which can be assayed by Transthoracic Doppler echocardiography. The symptoms of anxiety were measured with Self-rating Anxiety Scale (SAS) . According to the SAS score,the patients were divided into anxiety group and non-anxiety group.We assessed the association of anxiety with coronary microcirculatory function.
This was an open-label, phase IIIb, multicenter, single arm, historical-controlled study. Biopsy-confirmed BCC lesions (1 per subject) were excised by curettage, with no electrodessication. Approximately 1 week later, treatment with imiquimod 5% cream was initiated. Imiquimod was applied to the target BCC once daily, 5 times per week (5x/week) for up to 6 weeks. Rest periods were allowed as needed. Subjects reported to the study center at treatment weeks 1, 2, and 6, and posttreatment at weeks 12, 26, and 52. At treatment week 6 and all posttreatment visits, the investigator clinically assessed the target site for tumor clearance and cosmetic outcome. A template made at initiation and created from clear plastic overlay aided in locating the target tumor site. If the investigator identified a lesion that had occurred or recurred at the target site, the subject was discontinued from the study and counted as a recurrence/persistence (R/P).
In an investigation of the transformation of anergic patients (with no delayed hypersensitive reaction to skin-sensitizing antigens) into an allergic state (in which the above reaction is present, an effective amt. of 2,3,5,6-tetrahydro-6-phenylimidazo [2,1-b] thiazole (I), or its acid-addn. salts is administered to the patient and, after another challenge with the antigen (pref. 2,4-dinitrochlorobenzene or tuberculin), the patient is again examined for the required transformation. There is a connection between the ability of cancer patients to react to certain antigens and their operability, and (I) has been found to transform a statistically significant no. of anergic patients into positively reacting states.
All patients eligible for inclusion were treated with TR2-ICE, and the first efficacy evaluation was conducted after the second course of treatment. If the patient can achieve complete response (CR), partial response (PR), and disease stability (SD), the clinical benefit is considered, and the TR2-ICE treatment regimen is continued. The second efficacy assessment was performed after the 4th course of treatment. If patients achieved complete response (CR) or partial response (PR) compared to baseline, the clinical treatment was considered effective and the TR2-ICE treatment regimen was continued. After the completion of six courses of induction chemotherapy, an end-of-course assessment was performed. Patients with CR and PR can choose to undergo autologous hematopoietic stem cell transplantation consolidation therapy, or lenalidomide or Tirelarizin monotherapy or both combination maintenance therapy. If patients still had SD after four courses of treatment or PD at any time during the study, they were dropped out of the study and given salvage therapy.
The recommended intakes of energy, protein (15-25%), fat (30-40%) and carbohydrate (40-50%) will be similar to that in carbohydrate counting diet which mentioned above. DASH diet food choices will be inserted in the diet of the participants assigned for the combined diet of DASH and carbohydrate counting. The emphasis will be more on the fruits and vegetables group (\>8 servings/day), whole grains (at least half of the amount of the total servings of cereals; 6-8 servings/day), fat free dairy products (2-3 servings/day), lean meat and plant proteins (0-2 servings/day) and nuts (5-7 servings/week). From the fat group olive oil will represent the main type of fat (20-25% of total fat %). Adequate intake of sodium (2000mg) will be applied into participants' diet.
PROBLEM TO BE SOLVED: To obtain the subject composition having low irritation and an excellent antibacterial property by compounding the basic amino acid adduct (salt) of a specific epoxy compound and an antibacterial agent. SOLUTION: This antibacterial agent composition contains (A) the adduct (salt) of (i) an epoxy compound of formula I [R<1> is a 8-22C linear or branched alkyl or an alkenyl; (j) is 0 or 1] to (ii) a basic amino acid and (B) an antibacterial agent. The component ii is preferably arginine, lysine, etc. The component A is preferably a compound of formula II  X is H or a group of formula III; (k) is 0-5; Y is a group of formula IV [(m) is 1-5; Z is NH2 , groups of formulas V or the liked, when (k) is 0, and Y is further amino, when (k) is 1-5}. The component B is preferably benzalkonium chloride, triclosan, etc. The component A is preferably compounded in an amount of 0.01-10 wt.%. The component B is also preferably compounded in an amount of 0.01-5 wt.%, when the component B is the benzalkonium chloride or the triclosan.
Central pancreatectomy (CP) is indicated for benign or low-grade pancreatic tumors located in the neck or proximal pancreatic body. This procedure is demanding and has a high rate of postoperative complications. Minimally invasive surgery is now commonly used for CP but it is still unclear whether the robotic approach offers any advantages over conventional pancreatic minimally invasive surgery. Most studies on robotic CP are limited to case reports or case series; however, there are two important studies on this topic. Currently, the evidence on robotic CP remains limited, making it challenging to draw definitive conclusions in favor of one technique over the other. The use of a robotic platform, with its integrated tools such as intraoperative ultrasound, can guide the surgeon in performing this technically demanding procedure in a safer manner. The controversy regarding the best minimally invasive surgery approach for CP is still ongoing and requires further research.
The invention provides a cucurbitane triterpenoidA compound 1-11 is prepared by grinding fructus Momordicae Charantiae into powder, extracting in methanol, and extracting with ethyl acetate and water to obtain crude extracts of water layer and ester layer; separating and purifying the crude extracts respectively to obtain the compounds 1-11. The extraction method provided by the invention is simple and easy to operate and high in yield. The cucurbitane triterpenoid compound provided by the invention can obviously prolong the replicative life of yeast cells in an anti-aging in-vitro screening model. Can be applied to the preparation of anti-aging drugs and health products. Provides basis for research and development of new anti-aging drugs and basic research, and has important practical significance. The structural formula of the cucurbitane triterpenoid is as follows:
The present invention relates to a pharmaceutical composition and an application of Imrecoxib in the preparation of a drug for cervical spondylotic radiculopathy. The onset of cervical spondylotic radiculopathy is accompanied by shoulder pain and pain at the inner side of the scapula, manifesting as drilling pain or knife-like pain, which seriously affects the quality of life of a patient. Therefore, rapidly alleviating the pain symptoms of the patient and ensuring quality of life of the patient are important tasks for the treatment of cervical spondylotic radiculopathy. The present invention first provides an application of Imrecoxib in the treatment of cervical spondylotic radiculopathy. The present invention also provides a combined use method of Imrecoxib and a Mingren neck pain product. Further, the present invention provides a combination use of an Imrecoxib dispersion and a Mingren neck pain product, which can effectively relieve pain symptoms and reduces gastrointestinal irritation effects of the drug.
The invention relates to an intelligent medical care seeking system for a campus dispensary. The system comprises a student sub-terminal, a dispensary terminal and a control terminal. The student sub-terminal includes an identity information module, a prompting module and a first communication module; the dispensary terminal includes a second communication module, an identity verification module, a display module, and an input module, wherein the second communication module communicates with the first communication module, and the display module is used for displaying identity information and information of medical care seeking of a student, medicine consumption, skin test response, and drug allergy. The control terminal comprises a third communication module communicating with the first and second communication modules and comprises an information database of medical care seeking of students. When a student goes to the dispensary for medical care seeking, after the identity is verified, a doctor can easily call out medical care seeking information of the student from the information database of medical care seeking of students through the control terminal, and master information about medical care seeking of a student, medicine consumption, skin test response, and drug allergy. The doctor can fast and well prescribe, the cost is saved, and the treatment burden is released.
BACKGROUND: Small airways obstruction (SAO) is common in general populations. It has been associated with respiratory symptoms, cardiometabolic diseases, and progression to COPD over time. Whether SAO predicts mortality is largely unknown.
RESEARCH QUESTION: Is spirometry-defined SAO associated with increased mortality?
METHODS: Data were analyzed from 252,877 adult participants, aged 40 to 69 years at baseline, in the UK Biobank who had provided good-quality spirometry measurements. SAO was defined as the ratio of the forced expiratory volume in 3 s to the forced expiratory volume in 6 s less than the lower limit of normal. SAO was considered to be isolated if present when the FEV1/forced expiratory volume in 6 s ratio was normal (ie, greater than the lower limit of normal). A multivariable Cox regression model was used to assess the association of SAO, and isolated SAO, with all-cause and disease-specific mortality. Sex differences were investigated in these associations, and the primary analysis was repeated, excluding those who ever smoked. All models were adjusted for potential confounders such as sex, BMI, smoking status, smoking pack-years, assessment center, Townsend deprivation index, and ethnicity.
RESULTS: A total of 59,744 participants with SAO were identified, of whom 24,004 had isolated SAO. A total of 5,009 deaths were reported over a median of 12.8 years of follow-up. Participants with SAO had increased all-cause (hazard ratio [HR], 1.31; 95% CI, 1.26-1.36), cardiovascular (HR, 1.39; 95% CI, 1.29-1.51), respiratory (HR, 2.20; 95% CI, 1.92-2.51), and neoplasm (HR, 1.23; 95% CI, 1.17-1.29) mortality risk. These associations were not modified by sex. However, in those who never smoked, only respiratory and cardiovascular mortality risk was associated with SAO. Isolated SAO was also associated with an increased mortality risk (HR, 1.14; 95% CI, 1.07-1.20).
INTERPRETATION: Individuals with SAO have an increased risk of all-cause and disease-specific mortality. Further studies are needed to determine whether SAO causes mortality or is a marker of underlying disease.
FIELD: medicine, immunology. SUBSTANCE: invention relates to preparing and using the polysaccharide exudate purified fractions from plants of species Astragalus. Method of isolation, purification and modification of polysaccharide fraction of tragacanth resin from plants of species Astragalus involves removal of natural cations from a water-soluble fraction by ion-exchange resin, isolation of polysaccharide product by evaporation or precipitation with lower alcohol and extraction of polysaccharide product with lower alcohol taken from a group: methanol, ethanol and isopropanol for product sterilization and removal of remained low-molecular impurities. Invention describes also a composition based on polysaccharide resin fraction, method of inhibition of cancer tumor growth with this composition and a method of inhibition of viral infections. EFFECT: improved method of isolation, enhanced effectiveness of composition, broadened pattern of agents using against tumor diseases and viral infections. 18 cl, 8 tbl, 10 ex, 3 dwg
Highly efficient regulated promoters (RPs) and transactivators are provided. The RPs contain 2-8 transactivator binding domains positioned in an optimized manner with respect to each other. In a tetracycline-regulatable system, the RP displays 5- to 10-fold enhanced regulation efficiency by maintaining high maximal expression while offering 5- to 10-fold reduced basal leakiness. In transient studies, these novel promoters display over 900-fold gene regulation at 1:1 ratio of transactivator to reporter plasmid. Furthermore, these promoters preserve their regulator efficienty in the context of a single positive feedback regulatory vector that presents ease of delivery of the system for many uses, including for use in vivo and in gene therapy. Finally, humanized transactivators are provided, for example a tetracycline transactivator utilizing the human transactivational domain of NF-λ p65 protein fused to tetracycline repressor (terR) is provided that functions as efficiently as the tetracycline-regulated transactivator (tTA) and should reduce the potential immunogenicity of the original tTA.
OBJECTIVE: Type II endoleak (T2EL) is the most common type of endoleak after endovascular aneurysm repair (EVAR) and a common indication for reintervention due to late sac enlargement. Although pre-emptive embolization of the inferior mesenteric artery (IMA) has been proposed to prevent this, no studies have prospectively demonstrated its efficacy. This study aimed to prove the validity of IMA embolization during EVAR in selective cases by analyzing the mid-term outcomes of a randomized clinical trial (RCT).
METHODS: This single-center, parallel-group, non-blinded RCT included participants at high risk of T2EL, characterized by a patent IMA in conjunction with one or more following risk factors: a patent IMA ≥3 mm in diameter, lumbar arteries ≥2 mm in diameter, or an aortoiliac-type aneurysm. The participants were randomly assigned to two groups in a 1:1 ratio: one undergoing EVAR with IMA embolization and the other without. The primary endpoint was T2EL occurrence. The secondary endpoints included aneurysm sac changes and reintervention. In addition to RCT participants, outcomes of patients with low risk of T2EL were also analyzed.
RESULTS: The embolization and non-embolization groups each contained 53 patients. Five-year follow-up after the last patient enrollment revealed that T2ELs occurred in 28.3% and 54.7% of patients in the IMA embolization and non-embolization groups, respectively (P = .006). Both freedom from T2EL-related sac enlargement ≥5 mm and cumulative incidence of sac shrinkage ≥5 mm were significantly higher in the IMA embolization group than in the non-embolization group (95.5% vs 73.6% at 5 years; P = .021; 54.2% vs 33.6% at 5 years; P = .039, respectively). The freedom from T2EL-related sac enlargement ≥10 mm, an alternative indicator for T2EL-related reintervention, showed similar results (100% vs 90.4% at 5 years; P = .019). Outcomes in the low-risk group were preferable than those in the non-embolization group and comparable to those in the IMA embolization group.
CONCLUSIONS: A lower threshold for pre-emptive IMA embolization when implementing EVAR would be more appropriate if limited to patients at high risk of T2ELs.
The present invention is a system and method of related healthcare processes protecting workplace productivity and mental health. It provides tools to patients and their physicians to assist them in identifying, managing and tracking mental health disorders. It also provides information to employers and health and disability insurers regarding the most effective interventions promoting productivity and mental and physical health. Through an interactive process with a website, the patient undergoes an initial screening for the presence of a mental health disorder, in an anonymous and confidential manner. After the first stage of screening, if the possibility of a mental disorder is identified, questions will be posed to the patient to determine the level of risk for possible diagnosis of a mental disorder by the M.D. A printable diagnostic risk map is provided in addition to appropriate care maps and follow up maps that guide physician and patient management of these disorders. Compliance with current best practices in disease management by both patient and physician is supported by scientific information at the lay level and physician level. Clinical and functional outcomes are quantified economically. Outcomes are tracked individually, but only aggregate information is provided to the employer and/or insurer. The overall result is improved mental health, physical health, productivity for large populations in a cost effective manner without requiring changes to the existing health care systems
PURPOSE: Research on symptom clusters in oncology is progressing, but knowledge gaps remain. One question is whether the number and types of symptom subgroups (i.e., latent classes) differ based on cancer diagnosis. The purpose of this study was to: (1) identify and compare latent class subgroups based on four highly prevalent symptoms (pain, fatigue, sleep disturbance, and depression), and (2) examine the differences in sociodemographic and clinical factors in the identified latent classes across the seven cancer types (i.e., prostate, non-small cell lung, non-Hodgkin's lymphoma, breast, uterine, cervical, and colorectal cancer).
METHODS: This study is a cross-sectional secondary analysis of data obtained from the My-Health study in partnership with four Surveillance, Epidemiology, and End Results (SEER) cancer registries located in California (two), Louisiana, and New Jersey. The sample included 4,762 cancer survivors 6-13 months following diagnosis of one of the seven cancer types mentioned. Latent class profile analysis was used.
RESULTS: Subjects were primarily young (59% age 21-64 years), Caucasian (41%), married/cohabitating (58%) and unemployed (55%). The number and types of symptom subgroups varied across these seven cancer populations: four-subgroups were the common in prostate, lung, non-Hodgkin's lymphoma, and breast cancer survivors. Unmarried, low education, and unemployment status were associated with high risk of symptom burden across the cancer types.
CONCLUSION: Identifying symptom subgroups by cancer diagnosis has the potential to develop innovative and effective targeted interventions in cancer survivors. Further research is needed to establish extensive knowledge in symptom clustering between treatment regimens, and short-term and long-term cancer survivors.
<P>PROBLEM TO BE SOLVED: To provide a surface-modified inorganic oxide powder subjected to a surface treatment with a silicone oil, having a high fixation rate of the silicone oil and high hydrophobicity.  <P>SOLUTION: The inorganic oxide powder subjected to a surface treatment with a reactive modified silicone oil has a carbon fixation rate of not less than 90% and a hydrophobicity rate of not less than 95%. The inorganic oxide powder includes, preferably fumed silica. The surface-modified inorganic oxide powder is obtained by adding a reactive modified silicone oil to an inorganic oxide powder and subjecting the powder to a primary treatment at 150 to 280°C, followed by a secondary treatment over 280°C. By carrying out the surface treatment using the reactive modified silicone oil in a two-step treatment under predetermined temperature conditions, the obtained surface-modified inorganic oxide powder has a high fixation rate and high hydrophobicity.  <P>COPYRIGHT: (C)2010,JPO&INPIT